Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates

Chantal Cossette, Lisa A. Miller, Qiuji Ye, Shishir Chourey, Chintam Nagendra Reddy, Joshua Rokach, William S. Powell

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background and Purpose: The 5-lipoxygenase product, 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), is a potent chemoattractant for eosinophils and neutrophils. However, little is known about its pathophysiological role because of the lack of a rodent ortholog of the oxoeicosanoid (OXE) receptor. The present study aimed to determine whether the selective OXE receptor antagonist S-Y048 can inhibit allergen-induced pulmonary inflammation in a monkey model of asthma. Experimental Approach: Monkeys sensitized to house dust mite antigen (HDM) were treated with either vehicle or S-Y048 prior to challenge with aerosolized HDM, and bronchoalveolar (BAL) fluid was collected 24 h later. After 6 weeks, animals that had initially been treated with vehicle received S-Y048 and vice versa for animals initially treated with S-Y048. Eosinophils and neutrophils in BAL and lung tissue samples were evaluated, as well as mucus-containing cells in bronchi. Key Results: HDM significantly increased the numbers of eosinophils, neutrophils, and macrophages in BAL fluid 24 h after challenge. These responses were all significantly inhibited by S-Y048, which also reduced the numbers of eosinophils and neutrophils in lung tissue 24 h after challenge with HDM. S-Y048 also significantly reduced the numbers of bronchial epithelial cells staining for mucin and MUC5AC after antigen challenge. Conclusion and Implications: This study provides the first evidence that 5-oxo-ETE may play an important role in inducing allergen-induced pulmonary inflammation and could also be involved in regulating MUC5AC in goblet cells. OXE receptor antagonists such as S-Y048 may useful therapeutic agents in asthma and other eosinophilic as well as neutrophilic diseases.

Original languageEnglish (US)
Pages (from-to)322-336
Number of pages15
JournalBritish Journal of Pharmacology
Issue number2
StatePublished - Jan 2022
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates'. Together they form a unique fingerprint.

Cite this